Perwien Amy R, Kratochvil Christopher J, Faries Douglas E, Vaughan Brigette S, Spencer Thomas, Brown Ronald T
Outcomes Research, US Medical Division, Eli Lilly and Company, Indianapolis, Indiana, USA.
J Child Adolesc Psychopharmacol. 2006 Dec;16(6):713-24. doi: 10.1089/cap.2006.16.713.
Numerous investigations have examined the efficacy of pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD) in children. However, relatively few studies have addressed the impact of treatment on long-term subjective, psychosocial outcomes, such as health-related quality of life (HRQL). This study examines the long-term effects of pharmacological treatment with atomoxetine on HRQL in children and adolescents with ADHD.
Participants included 6- to 17-year-old children and adolescents (n = 912) with ADHD enrolled in a 24-month, multicenter, open-label trial of atomoxetine. Outcomes included clinician ratings of ADHD, parent ratings of ADHD, and a widely used measure of HRQL (The Child Health Questionnaire (CHQ)). Treatment response rates were calculated based on a CHQ improvement of at least 1 standard error of measurement.
Significant improvements in HRQL were found following both acute and long-term treatment for psychosocial but not physical health. Of participants who completed treatment (n = 312 or 34.2% of those enrolled), 81% responded to acute treatment and 78% responded to long-term treatment. Improvements noted after acute treatment were maintained during long-term treatment with the majority of participants (86%) continuing to respond to treatment.
Atomoxetine is associated with improvements in HRQL, and the improvements are generally stable over time.
众多研究探讨了药物治疗儿童注意力缺陷多动障碍（ADHD）的疗效。然而，相对较少的研究关注治疗对长期主观、心理社会结局的影响，如健康相关生活质量（HRQL）。本研究考察了用托莫西汀进行药物治疗对ADHD儿童和青少年HRQL的长期影响。
参与者包括6至17岁患有ADHD的儿童和青少年（n = 912），他们参加了一项为期24个月的托莫西汀多中心开放标签试验。结局指标包括临床医生对ADHD的评分、家长对ADHD的评分，以及一种广泛使用的HRQL测量工具（儿童健康问卷（CHQ））。治疗反应率根据CHQ至少提高1个测量标准误来计算。
在对心理社会健康而非身体健康进行急性和长期治疗后，发现HRQL有显著改善。在完成治疗的参与者中（n = 312，占入组者的34.2%），81%对急性治疗有反应，78%对长期治疗有反应。急性治疗后观察到改善在长期治疗期间得以维持，大多数参与者（86%）继续对治疗有反应。
托莫西汀与HRQL的改善相关，且这种改善通常随时间推移保持稳定。
